JP2014159478A5 - - Google Patents

Download PDF

Info

Publication number
JP2014159478A5
JP2014159478A5 JP2014111127A JP2014111127A JP2014159478A5 JP 2014159478 A5 JP2014159478 A5 JP 2014159478A5 JP 2014111127 A JP2014111127 A JP 2014111127A JP 2014111127 A JP2014111127 A JP 2014111127A JP 2014159478 A5 JP2014159478 A5 JP 2014159478A5
Authority
JP
Japan
Prior art keywords
biological system
animal
seq
acid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014111127A
Other languages
English (en)
Japanese (ja)
Other versions
JP6073833B2 (ja
JP2014159478A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014159478A publication Critical patent/JP2014159478A/ja
Publication of JP2014159478A5 publication Critical patent/JP2014159478A5/ja
Application granted granted Critical
Publication of JP6073833B2 publication Critical patent/JP6073833B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2014111127A 2005-02-16 2014-05-29 ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用 Expired - Fee Related JP6073833B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65347905P 2005-02-16 2005-02-16
US60/653,479 2005-02-16

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011264338A Division JP5852426B2 (ja) 2005-02-16 2011-12-02 ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016183644A Division JP6250764B2 (ja) 2005-02-16 2016-09-21 ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用

Publications (3)

Publication Number Publication Date
JP2014159478A JP2014159478A (ja) 2014-09-04
JP2014159478A5 true JP2014159478A5 (https=) 2014-11-13
JP6073833B2 JP6073833B2 (ja) 2017-02-01

Family

ID=36917026

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2007556264A Expired - Fee Related JP5063366B2 (ja) 2005-02-16 2006-02-16 ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用
JP2011264338A Expired - Fee Related JP5852426B2 (ja) 2005-02-16 2011-12-02 ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用
JP2014111127A Expired - Fee Related JP6073833B2 (ja) 2005-02-16 2014-05-29 ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用
JP2016183644A Expired - Fee Related JP6250764B2 (ja) 2005-02-16 2016-09-21 ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2007556264A Expired - Fee Related JP5063366B2 (ja) 2005-02-16 2006-02-16 ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用
JP2011264338A Expired - Fee Related JP5852426B2 (ja) 2005-02-16 2011-12-02 ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016183644A Expired - Fee Related JP6250764B2 (ja) 2005-02-16 2016-09-21 ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用

Country Status (7)

Country Link
US (6) US7968091B2 (https=)
EP (3) EP2954903A1 (https=)
JP (4) JP5063366B2 (https=)
CA (1) CA2597925A1 (https=)
ES (2) ES2392096T3 (https=)
HK (1) HK1218875A1 (https=)
WO (1) WO2006088972A2 (https=)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7981420B2 (en) 2000-12-22 2011-07-19 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)
EP1392345B2 (en) * 2001-05-25 2018-02-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
WO2006088972A2 (en) * 2005-02-16 2006-08-24 The General Hospital Corporation Use of modulatirs of compounds of tgf-beta superfamily to regulate hepcidin-mediated iron metabolism
US20070099245A1 (en) * 2005-09-29 2007-05-03 Boris Gorovits Assays for neutralizing antibodies
EP1928905B1 (de) 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
ES2649983T3 (es) 2005-11-23 2018-01-16 Acceleron Pharma, Inc. Antagonistas de activina-ActRIIa en su uso para promover el crecimiento óseo
CN104524548A (zh) 2006-12-18 2015-04-22 阿塞勒隆制药公司 活化素-actrii拮抗剂及在提高红细胞水平中的用途
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
MX2009008222A (es) 2007-02-01 2009-10-12 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
EA018221B1 (ru) 2007-02-09 2013-06-28 Акселерон Фарма Инк. АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ
WO2008124768A1 (en) * 2007-04-09 2008-10-16 The General Hospital Corporation Hemojuvelin fusion proteins and uses thereof
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
TW201803586A (zh) 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
JP6018753B2 (ja) * 2008-11-13 2016-11-02 ザ・ジェネラル・ホスピタル・コーポレイションＴｈｅ Ｇｅｎｅｒａｌ Ｈｏｓｐｉｔａｌ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｍｐ−６の調節によって鉄の恒常性を制御するための方法および組成物
US20110293526A1 (en) * 2008-11-20 2011-12-01 University Of Southern California Compositions and methods to modulate hair growth
AU2010204985A1 (en) 2009-01-13 2011-08-04 Acceleron Pharma Inc. Methods for increasing adiponectin
KR20120049214A (ko) 2009-06-08 2012-05-16 악셀레론 파마 인코포레이티드 발열성 지방세포를 증가시키는 방법
KR20180026795A (ko) 2009-06-12 2018-03-13 악셀레론 파마 인코포레이티드 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
EP3332796A1 (en) 2009-11-17 2018-06-13 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
MX2012006560A (es) * 2009-12-08 2012-10-05 Abbott Gmbh & Co Kg Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
AU2011326586A1 (en) 2010-11-08 2013-05-30 Acceleron Pharma, Inc. ActRIIA binding agents and uses thereof
AU2012251919B2 (en) 2011-01-19 2016-12-15 Ferrumax Pharmaceuticals, Inc. Compositions for regulating iron homeostasis and methods of using same
CA2855570A1 (en) * 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
CA3204283A1 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
EP3369746A1 (en) 2012-01-27 2018-09-05 AbbVie Deutschland GmbH & Co KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
ES2731609T3 (es) * 2012-11-01 2019-11-18 Univ California Polipéptidos ERFE y eritroferrona y métodos de regulación del metabolismo del hierro
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
AR093620A1 (es) 2012-12-17 2015-06-10 Lilly Co Eli Anticuerpos bmp-6
EP2976085A1 (en) * 2013-03-21 2016-01-27 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
JP6518656B2 (ja) * 2013-06-13 2019-05-22 バイオデシー， インコーポレイテッド 標的生体実体を標的にする生化学実体候補をスクリーニングする方法
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
WO2016106286A1 (en) 2014-12-23 2016-06-30 Biodesy, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
EP3307070B1 (en) 2015-06-12 2025-10-29 Emory University Growth and survival compositions for cells capable of producing antibodies and methods related thereto
US20200231652A1 (en) 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
UA123219C2 (uk) * 2015-10-23 2021-03-03 Віфор (Інтернаціональ) Аґ Інгібітори феропортину
WO2017147078A1 (en) 2016-02-22 2017-08-31 Brigham Young University Method and compositions for the treatment of anemia through the inhibition of furin
AU2017283787B2 (en) 2016-06-15 2020-09-17 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
AU2018228435C1 (en) 2017-03-02 2025-09-18 National Research Council Of Canada TGF-beta-receptor ectodomain fusion molecules and uses thereof
US11125757B2 (en) 2017-05-26 2021-09-21 Emory University Methods of culturing and characterizing antibody secreting cells
EP3870181B1 (en) 2018-10-26 2024-08-14 Keros Therapeutics, Inc. Crystal forms of an alk2 inhibitor
EP4041243A4 (en) * 2019-09-27 2023-10-18 Disc Medicine, Inc. METHODS OF TREATMENT OF ANEMIA OF CHRONIC DISEASE
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
WO2022098821A1 (en) * 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating lymphopenia
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
EP0414297B1 (en) 1989-08-11 1996-10-16 Gist-Brocades N.V. Efficient production of mutant proteases
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
JPH09500007A (ja) 1993-04-19 1997-01-07 スチュアート エイ コーフマン 新規化合物生成に関するランダム化学
BR9407947A (pt) 1993-11-02 1996-11-26 Affymax Tech Nv Processo para sintetizar moléculas diversas em uma pluralidade de substratos e uma coleçao molecular etiquetade para realizaçao reaçoes de copulaçao em contas em paralelo para triar uma coleçao molecular etiquetada para detectar a presença de um ou mais diferentes etiquetas e para determinar a sequência de síntese aparelho para reaçoes de copulaçao paralelas em suportes sólidos bloco de alinhamento ótico para uso com um detector ótico sistemas de distribuiçao para distribuir reagentes dispositiv
WO1998033918A1 (en) 1997-02-05 1998-08-06 The Regents Of The University Of California Morphogenic proteins
EP1130094A3 (en) 1999-07-08 2001-11-21 Helix Research Institute Primers for synthesizing full length cDNA clones and their use
EP1251863A4 (en) 2000-01-31 2005-03-02 Human Genome Sciences Inc 22 HUMAN SECRETED PROTEINS
WO2002077006A1 (en) 2001-03-23 2002-10-03 Human Genome Sciences, Inc. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US6800455B2 (en) 2000-03-31 2004-10-05 Scios Inc. Secreted factors
CN1159063C (zh) * 2000-06-21 2004-07-28 中国医学科学院血液学研究所 骨形态发生蛋白（bmp）作为治疗急性再生障碍性贫血药物的应用
US7981420B2 (en) 2000-12-22 2011-07-19 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)
EP1392345B2 (en) 2001-05-25 2018-02-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
WO2003000461A1 (fr) 2001-06-21 2003-01-03 Meiyu-Giken Co., Ltd. Procede de polissage de la surface d'extremite de connexion d'un connecteur a fibres optiques, structure optique et structure heterogene coaxiale de couches de materiau, et dispositif de polissage
US20040248249A1 (en) 2001-07-05 2004-12-09 Tran Uyen K Secreted proteins
JP2003135075A (ja) 2001-11-05 2003-05-13 Research Association For Biotechnology 新規な全長ｃＤＮＡ
WO2003089608A2 (en) 2002-04-18 2003-10-30 The General Hospital Corporation Drg11-responsive (dragon) gene family
WO2004003150A2 (en) 2002-06-26 2004-01-08 Yale University Modulators and modulation of the interacton between rgm and neogenin
DE10230381A1 (de) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen
GB0217786D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
AU2004231122B2 (en) 2003-04-15 2010-04-08 Xenon Pharmaceuticals Inc. Juvenile hemochromatosis gene (HFE2A), expression products and uses thereof
WO2005028517A2 (en) * 2003-05-09 2005-03-31 The General Hospital Corporation SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS
US20060063208A1 (en) 2004-08-02 2006-03-23 Woolf Clifford J DRG11-responsive (DRAGON) gene and uses thereof
WO2006088972A2 (en) * 2005-02-16 2006-08-24 The General Hospital Corporation Use of modulatirs of compounds of tgf-beta superfamily to regulate hepcidin-mediated iron metabolism
CA2549477A1 (en) 2005-06-29 2006-12-29 The Regents Of The University Of California Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin

Similar Documents

Publication Publication Date Title
JP2014159478A5 (https=)
Jawa et al. T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation
HRP20210057T4 (hr) Presađivanje stem stanica s kombinacijom sredstva koje cilja stem stanice i modulacija imunoregulatorne signalizacije
NZ629261A (en) Pharmaceutical formulations of tnf-alpha antibodies
WO2017058892A3 (en) Methods and compositions for antibody-evading virus vectors
JP2011136997A5 (https=)
JP2018520648A5 (https=)
JP2018520997A5 (https=)
BR112015023140A2 (pt) proteínas de fusão il-22 fc, método para fabricar a proteína de fusão il-22 fc monomérica, composição, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar uma proteína de fusão il-22 fc, composições farmacêuticas e usos de uma composição farmacêutica
JP2015519878A5 (https=)
JP2021503485A5 (https=)
MX392628B (es) Amortiguador de lavado de cromatografia de afinidad.
WO2014160490A8 (en) Antibody formulations
Criscitiello et al. Deiminated proteins in extracellular vesicles and serum of llama (Lama glama)—Novel insights into camelid immunity
JP2020520680A5 (https=)
WO2016100328A8 (en) Novel tilapia virus and uses thereof
JP2018531624A5 (https=)
EA201491513A1 (ru) Рекомбинантные штаммы escherichia coli
JP2014504297A5 (https=)
MA32770B1 (fr) Anticorps anti-peptides igf-1/e humain modifie
MX2018013177A (es) Proteina de fusion que contiene variante ccl3 y uso de la misma referencia cruzada para aplicaciones relacionadas.
RU2016148598A (ru) Способ лиофилизации генно-терапевтического препарата, представляющего собой комплекс плазмидной ДНК и блок-сополимера ПЭГ-ПЭИ (полиэтилгликоль-полиэтиленимин)
JP2017500030A5 (https=)
JP2018512844A5 (https=)
Lee et al. Transcriptional analysis of olive flounder lectins in response to VHSV infection